dc.creator | Hadjigeorgiou, G. H. | en |
dc.creator | Xiromerisiou, G. | en |
dc.creator | Gourbali, V. | en |
dc.creator | Aggelakis, K. | en |
dc.creator | Scarmeas, N. | en |
dc.creator | Papadimitriou, A. | en |
dc.creator | Singleton, A. | en |
dc.date.accessioned | 2015-11-23T10:29:22Z | |
dc.date.available | 2015-11-23T10:29:22Z | |
dc.date.issued | 2006 | |
dc.identifier | 10.1002/mds.20752 | |
dc.identifier.issn | 8853185 | |
dc.identifier.uri | http://hdl.handle.net/11615/28283 | |
dc.description.abstract | The α-synuclein Rep1 polymorphism was studied in patients and controls in an ethnic Greek population. There was an association of allele 2 with risk of Parkinson's disease (PD; adjusted odd ratio = 3.25; 95% CI = 1.80-5.87). Survival analyses (Cox proportional hazards models) were employed to explore the influence of genotypes on age at onset of PD. Age at onset of carriers of at least one Rep1 allele 2 was earlier (3.6 years) compared to noncarriers (adjusted hazard ratio = 2.21; 95% CI = 1.58-3.10). Kaplan-Meier analysis also supported a dosage effect of Rep1 allele 2 on age at onset. For Rep1 allele 1, there was neither association with risk of PD nor influence on age at onset. This is the first study showing an influence of Rep1 polymorphism on age at onset of PD. © 2005 Movement Disorder Society. | en |
dc.source | Movement Disorders | en |
dc.source.uri | http://www.scopus.com/inward/record.url?eid=2-s2.0-33646249380&partnerID=40&md5=a0edd80743ee235bd0e1f528cdd137d1 | |
dc.subject | α-synuclein | en |
dc.subject | Association study | en |
dc.subject | Parkinson's disease | en |
dc.subject | Rep1, polymorphism | en |
dc.subject | alpha synuclein | en |
dc.subject | protein Rep 1 | en |
dc.subject | unclassified drug | en |
dc.subject | adult | en |
dc.subject | aged | en |
dc.subject | analysis of variance | en |
dc.subject | article | en |
dc.subject | confidence interval | en |
dc.subject | controlled study | en |
dc.subject | disease association | en |
dc.subject | disease carrier | en |
dc.subject | ethnology | en |
dc.subject | female | en |
dc.subject | gene frequency | en |
dc.subject | genetic polymorphism | en |
dc.subject | genome analysis | en |
dc.subject | genotype | en |
dc.subject | Greece | en |
dc.subject | high risk population | en |
dc.subject | human | en |
dc.subject | Kaplan Meier method | en |
dc.subject | major clinical study | en |
dc.subject | male | en |
dc.subject | nucleotide sequence | en |
dc.subject | onset age | en |
dc.subject | Parkinson disease | en |
dc.subject | population research | en |
dc.subject | priority journal | en |
dc.subject | promoter region | en |
dc.subject | protein function | en |
dc.subject | risk assessment | en |
dc.subject | survival rate | en |
dc.subject | Age of Onset | en |
dc.subject | Aged, 80 and over | en |
dc.subject | alpha-Synuclein | en |
dc.subject | Case-Control Studies | en |
dc.subject | Chi-Square Distribution | en |
dc.subject | Confidence Intervals | en |
dc.subject | Genetic Predisposition to Disease | en |
dc.subject | Humans | en |
dc.subject | Microsatellite Repeats | en |
dc.subject | Middle Aged | en |
dc.subject | Odds Ratio | en |
dc.subject | Polymorphism, Genetic | en |
dc.subject | Promoter Regions (Genetics) | en |
dc.subject | Survival Analysis | en |
dc.title | Association of α-synuclein Rep1 polymorphism and Parkinson's disease: Influence of Rep1 on age at onset | en |
dc.type | journalArticle | en |